Orient Europharma Co Ltd (4120) — Cash Flow-to-Debt Ratio
Orient Europharma Co Ltd (4120) has a Cash Flow-to-Debt Ratio of -0.03x as of September 2025, meaning its operating cash flow of NT$-157.84 Million could theoretically repay 0% of its total liabilities (NT$4.54 Billion) in one year. See 4120 financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Orient Europharma Co Ltd Cash Flow-to-Debt Ratio (2015–2024)
Historical debt coverage capacity for Orient Europharma Co Ltd across 10 annual periods. For the full cash flow conversion analysis, see 4120 cash generation efficiency.
Annual Cash Flow-to-Debt Ratio for Orient Europharma Co Ltd (2015–2024)
Year-by-year debt coverage analysis for Orient Europharma Co Ltd. Check Orient Europharma Co Ltd cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.02x | NT$-121.11 Million | NT$5.75 Billion | ▼ -316.7% |
| 2023 | 0.01x | NT$64.67 Million | NT$6.65 Billion | ▲ +131.1% |
| 2022 | -0.03x | NT$-218.75 Million | NT$6.99 Billion | ▼ -339.9% |
| 2021 | 0.01x | NT$77.65 Million | NT$5.95 Billion | ▼ -90.9% |
| 2020 | 0.14x | NT$608.55 Million | NT$4.25 Billion | ▲ +155.5% |
| 2019 | 0.06x | NT$227.37 Million | NT$4.06 Billion | ▼ -25.0% |
| 2018 | 0.07x | NT$231.31 Million | NT$3.10 Billion | ▼ -68.2% |
| 2017 | 0.24x | NT$601.08 Million | NT$2.56 Billion | ▲ +443.4% |
| 2016 | 0.04x | NT$111.24 Million | NT$2.57 Billion | ▼ -86.0% |
| 2015 | 0.31x | NT$643.97 Million | NT$2.09 Billion | — |